Alkermes News

Amylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTAA injection taken twice daily, in patients with type 2 diabetes .

It seems the Food and Drug Administration may have misread Eli Lilly 's New Drug Application.

Last weeka TMs top five guru bargain stocks were Coinstar Inc, Fair Isaac Corp, Alkermes Inc, American International Group Inc, and Cal Dive International Inc.

Company and People Notes: PhRMA adds biopharm members; Dow spins off expression technology; and more.

The event will take place from... LOS ANGELES-- --Universal Detection Technology , a developer of early-warning monitoring technologies to protect people from bioterrorism and other infe... MASHANTUCKET, Conn.-- --For the second consecutive year, the acclaimed Craftsteak restaurant at the MGM Grand at Foxwoods has received the coveted AAA-Four ...

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Alkermes, Inc. and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion technology, which is designed to extend the circulating half-life of proteins and peptides.

Biotechnology concern Alkermes Inc. has invested $10 million for the licensing rights to a drug-development technology produced by Acceleron Pharma Inc.

Platforms aren't just for acrobatic moves before splashing into the pool or '70s night at the disco.

Shares of the following companies are having unusual moves in U.S. trading this morning.

STOCK MARKETING INC PRESENTS : Matech Corp., Alkermes, Inc.,, Altera Corp., Amazon.com, Inc., ANSYS, Inc., Apollo Group, Inc.

Alkermes, Inc. announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders.

Alkermes Inc. has begun a Phase 2 clinical study of ALKS 33, the Cambridge biotech's drug candidate for treating alcohol dependence and other central nervous system disorders.

Here is a list of stocks which traded higher Tuesday November 17, 2009 on unusually higher volume.

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, small-cap biotech Alkermes has earned a respected four-star ranking .

Drug stocks dipped in early action Tuesday, while shares of Alkermes Inc. gained for the second day on positive news about two of its substance-abuse therapies.

On 11/16/09, Cytori Therapeutics completed enrollment in a 70-patient, international breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer.

Ivanhoe Mines Ltd., a Canada-based mining company, said Friday that its third-quarter loss narrowed as it recorded revenue and decreased its exploration expenses.

OptionMonster co-founder Pete Najarian provides options picks Monday, Wednesday and Friday in TheStreet.com's Deep in the Money Calls newsletter.

Alkermes, Inc. announced today that its corporate presentation will be webcast live by Lazard Capital Markets on Tuesday, November 17, 2009, at 3:10 p.m. ET from the St.